150 related articles for article (PubMed ID: 28454726)
1. Predictive Value of Early Tumor Shrinkage and Density Reduction of Lung Metastases in Patients With Metastatic Colorectal Cancer Treated With Regorafenib.
Vanwynsberghe H; Verbeke X; Coolen J; Van Cutsem E
Clin Colorectal Cancer; 2017 Dec; 16(4):377-380. PubMed ID: 28454726
[TBL] [Abstract][Full Text] [Related]
2. Changes in CT morphology can be an independent response marker for patients receiving regorafenib for colorectal liver metastases: retrospective pilot study.
Ozaki Y; Shindoh J; Gonoi W; Nishioka Y; Kondoh C; Tanabe Y; Matoba S; Kuroyanagi H; Hashimoto M; Takano T
BMC Cancer; 2018 Feb; 18(1):138. PubMed ID: 29402244
[TBL] [Abstract][Full Text] [Related]
3. Clinical and molecular assessment of regorafenib monotherapy.
Kakizawa N; Suzuki K; Fukui T; Takayama Y; Ichida K; Muto Y; Hasegawa F; Watanabe F; Kikugawa R; Tsujinaka S; Futsuhara K; Miyakura Y; Noda H; Rikiyama T
Oncol Rep; 2017 Apr; 37(4):2506-2512. PubMed ID: 28259999
[TBL] [Abstract][Full Text] [Related]
4. Regorafenib Versus Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: A Retrospective Comparison.
Masuishi T; Taniguchi H; Hamauchi S; Komori A; Kito Y; Narita Y; Tsushima T; Ishihara M; Todaka A; Tanaka T; Yokota T; Kadowaki S; Machida N; Ura T; Fukutomi A; Ando M; Onozawa Y; Tajika M; Yasui H; Muro K; Mori K; Yamazaki K
Clin Colorectal Cancer; 2017 Jun; 16(2):e15-e22. PubMed ID: 27670892
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy rechallenge after regorafenib treatment in metastatic colorectal cancer: still hope after the last hope?
Bertocchi P; Aroldi F; Prochilo T; Meriggi F; Beretta GD; Zaniboni A
J Chemother; 2017 Apr; 29(2):102-105. PubMed ID: 28032528
[TBL] [Abstract][Full Text] [Related]
6. Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program.
Adenis A; de la Fouchardiere C; Paule B; Burtin P; Tougeron D; Wallet J; Dourthe LM; Etienne PL; Mineur L; Clisant S; Phelip JM; Kramar A; Andre T
BMC Cancer; 2016 Jul; 16():412. PubMed ID: 27389564
[TBL] [Abstract][Full Text] [Related]
7. Reduced dose of salvage-line regorafenib monotherapy for metastatic colorectal cancer in Japan.
Hirano G; Makiyama A; Makiyama C; Esaki T; Oda H; Uchino K; Komoda M; Tanaka R; Matsushita Y; Mitsugi K; Shibata Y; Kumagai H; Arita S; Ariyama H; Kusaba H; Akashi K; Baba E
Anticancer Res; 2015 Jan; 35(1):371-7. PubMed ID: 25550574
[TBL] [Abstract][Full Text] [Related]
8. Computed tomography densitometric study of anti-angiogenic effect of regorafenib in colorectal cancer liver metastasis.
Reginelli A; Clemente A; Cardone C; Urraro F; Izzo A; Martinelli E; Troiani T; Ciardiello F; Brunese L; Cappabianca S
Future Oncol; 2018 Dec; 14(28):2905-2913. PubMed ID: 29433345
[TBL] [Abstract][Full Text] [Related]
9. Optimizing Treatment Sequence for Late-line Metastatic Colorectal Cancer Patients Using Trifluridine/Tipiracil and Regorafenib.
Unseld M; Drimmel M; Siebenhüner A; Gleiss A; Bianconi D; Kieler M; Scheithauer W; Winder T; Prager GW
Clin Colorectal Cancer; 2018 Dec; 17(4):274-279. PubMed ID: 30042010
[TBL] [Abstract][Full Text] [Related]
10. Serum CA19-9 Response Is an Early Predictive Marker of Efficacy of Regorafenib in Refractory Metastatic Colorectal Cancer.
Komori A; Taniguchi H; Hamauchi S; Masuishi T; Kito Y; Narita Y; Tsushima T; Ishihara M; Todaka A; Tanaka T; Yokota T; Kadowaki S; Machida N; Ura T; Fukutomi A; Ando M; Onozawa Y; Tajika M; Yasui H; Muro K; Mori K; Yamazaki K
Oncology; 2017; 93(5):329-335. PubMed ID: 28866662
[TBL] [Abstract][Full Text] [Related]
11. Metastatic colorectal cancer responsive to regorafenib for 2 years: a case report.
Yoshino K; Manaka D; Kudo R; Kanai S; Mitsuoka E; Kanto S; Hamasu S; Konishi S; Nishitai R
J Med Case Rep; 2017 Aug; 11(1):227. PubMed ID: 28818109
[TBL] [Abstract][Full Text] [Related]
12. Total lesion glycolysis (TLG) as an imaging biomarker in metastatic colorectal cancer patients treated with regorafenib.
Lim Y; Bang JI; Han SW; Paeng JC; Lee KH; Kim JH; Kang GH; Jeong SY; Park KJ; Kim TY
Eur J Nucl Med Mol Imaging; 2017 May; 44(5):757-764. PubMed ID: 27888325
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Regorafenib or TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies.
Sueda T; Sakai D; Kudo T; Sugiura T; Takahashi H; Haraguchi N; Nishimura J; Hata T; Hayashi T; Mizushima T; Doki Y; Mori M; Satoh T
Anticancer Res; 2016 Aug; 36(8):4299-306. PubMed ID: 27466548
[TBL] [Abstract][Full Text] [Related]
14. Prophylactic Use of Oral Dexamethasone to Alleviate Fatigue During Regorafenib Treatment for Patients With Metastatic Colorectal Cancer.
Fukuoka S; Shitara K; Noguchi M; Kawazoe A; Kuboki Y; Bando H; Okamoto W; Kojima T; Doi T; Ohtsu A; Yoshino T
Clin Colorectal Cancer; 2017 Jun; 16(2):e39-e44. PubMed ID: 27780748
[TBL] [Abstract][Full Text] [Related]
15. Unexpected and durable response with regorafenib in a metastatic colorectal cancer patient without KDR mutation: A case report.
Rosati G; Del Gaudio N; Scarano E; Cifarelli RA; Altucci L; Bilancia D
Medicine (Baltimore); 2018 Jun; 97(25):e11178. PubMed ID: 29924031
[TBL] [Abstract][Full Text] [Related]
16. Multicenter Cohort Study to Assess the Association between Changes on Imaging and Outcome after Regorafenib Treatment (KSCC1603).
Oki E; Kawahira M; Kusumoto T; Yuki S; Hatanaka K; Kobayashi Y; Nishie A; Kawanami S; Makiyama A; Saeki H; Sakamoto S; Komatsu Y; Shimokawa M; Mori M; Esaki T
Oncology; 2020; 98(10):719-726. PubMed ID: 32640458
[TBL] [Abstract][Full Text] [Related]
17. [Successful Administration of Regorafenib to a Metastatic Colon Cancer Patient with Impaired Performance Status by Reducing the Initial Dose].
Nishitai R; Manaka D; Kudo R; Mitsuoka E; Kanai S; Kanto S; Yoshino K; Hamasu SY; Konishi S; Yamashiro Y
Gan To Kagaku Ryoho; 2015 Jul; 42(7):871-3. PubMed ID: 26197753
[TBL] [Abstract][Full Text] [Related]
18. Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer.
Suenaga M; Mashima T; Kawata N; Wakatsuki T; Horiike Y; Matsusaka S; Dan S; Shinozaki E; Seimiya H; Mizunuma N; Yamaguchi K; Yamaguchi T
Oncotarget; 2016 Jun; 7(23):34811-23. PubMed ID: 27166185
[TBL] [Abstract][Full Text] [Related]
19. Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial.
Argilés G; Saunders MP; Rivera F; Sobrero A; Benson A; Guillén Ponce C; Cascinu S; Van Cutsem E; Macpherson IR; Strumberg D; Köhne CH; Zalcberg J; Wagner A; Luigi Garosi V; Grunert J; Tabernero J; Ciardiello F
Eur J Cancer; 2015 May; 51(8):942-9. PubMed ID: 25818084
[TBL] [Abstract][Full Text] [Related]
20. Relation between sarcopenia and dose-limiting toxicity in patients with metastatic colorectal cancer who received regorafenib.
Gökyer A; Küçükarda A; Köstek O; Hacıoğlu MB; Sunal BS; Demircan NC; Uzunoğlu S; Solak S; İşsever K; Çiçin I; Erdoğan B
Clin Transl Oncol; 2019 Nov; 21(11):1518-1523. PubMed ID: 30868388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]